DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19.

ABSTRACT: Importance: There is an unprecedented need to rapidly identify safe and effective treatments for the novel coronavirus disease 2019 (COVID-19). Objective: To systematically investigate if any of the available drugs in Electronic Health Record (EHR), including prescription drugs and dietary supplements, can be repurposed as potential treatment for COVID-19. Design, Setting, and Participants: Based on a retrospective cohort analysis of EHR data, drug-wide association studies (DrugWAS) were performed on COVID-19 patients at Vanderbilt University Medical Center (VUMC). For each drug study, multivariable logistic regression with overlap weighting using propensity score was applied to estimate the effect of drug exposure on COVID-19 disease outcomes. Exposures: Patien

SUBMITTER: Bejan CA 

PROVIDER: S-EPMC7872383 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature